Kenneth Schultz

NIH Rank #1367

Researcher identity and coverage

Current affiliation: Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity: Profile ID 77812017Search this ID in NIH RePORTER
ScienceDex PI coverage: FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

Linked Award Amount

$5.1M

Full award amounts, FY2025

Award Records

Records listing this PI

Award-Linked Rank

#1,367

By linked amount among FY2025 PIs

Earliest Year Loaded

2024

ScienceDex PI coverage

Linked NIH award amounts and rank by fiscal year.

NIH award records listing Kenneth Schultz as a PI. Multi-PI records show the full award amount for context.

1R44CA302066-01R44
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors
Trethera Corporation
$1.2M
award amount
5R44AI186534-02R44
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)
Trethera Corporation
$1M
award amount
1R44AI188587-01A1R44
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus
Trethera Corporation
$995K
award amount
2R42DK138578-02R42
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease
Trethera Corporation
$905.3K
award amount
5R42EY034397-03R42
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis
Trethera Corporation
$622.4K
award amount
1R44CA306475-01R44
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancer
Trethera Corporation
$406.5K
award amount

Organizations that administered FY2025 awards listing Kenneth Schultz as a PI.

FY2025 award administered by Trethera Corporation (CA).

Computed from the fiscal years currently available in ScienceDex.

Search NIH-funded principal investigators by topic, department, or activity.

Compare median NIH grant budgets across departments, mechanisms, and years.